Tracy s. Warren, General Partner

Tracy Warren focuses primarily on health & life sciences and emerging energy technologies, and has led investments in seven companies, including university and government laboratory spin-outs Endovalve (cardiovascular devices / University of Pennsylvania), Superprotonic (solid acid fuel cells / California Institute of Technology), BioNanomatrix (DNA sequence analysis / Princeton University) and NellOne Therapeutics (regenerative medicine / U.S. DOE Oak Ridge National Laboratory).

While those investments demonstrated her specific acumen for identifying and dealing with issues surrounding intellectual property, tech transfer and commercialization, Warren's additional skills as a strong syndicate partner helped to add NuPathe (CNS specialty pharmaceutical), SmartSynch (utility smart metering) and Metatomix (semantic middleware) to the portfolio.

With the funding of Endovalve, Warren pioneered the fund's virtual company investment model, in which typical infrastructure expenses are minimized during a company's initial high-risk phase. For example, Endovalve limited its staff to two executives and outsourced R&D, prototype design and fabrication, not only cutting start-up costs, but also dramatically accelerating product development. She used this capital-efficient model again in 2008 with NellOne, for which she is acting chief executive officer.

Besides sitting on the Boards of BioNanomatrix, Endovalve, Metatomix and NellOne, and being a NuPathe, SmartSynch and Superprotonic Board observer, Warren is active in the venture and life-sciences communities. She is a member of: the selection and investor relations committees for the Southeast BIO 10th Anniversary Investor Forum; the New Jersey Technology Council's venture capital & finance advisory board; the Ben Franklin Technology Partners biotechnology and life sciences investment advisory committee; and the program committee for the American Society for Artificial Internal Organs 55th Annual Conference. She also co-chairs the life sciences screening committee for the 2008 Mid-Atlantic Capital Conference.

Warren started in venture capital in 2001 after focusing on companies in the medical device and health care information technology fields as an analyst and associate in SG Cowen Securities & Health Care Mergers and Acquisitions and Corporate Finance divisions. Prior to SG Cowen, she was in the Global Financial Analyst program at Chase Manhattan Bank and holds a B.S. degree in accounting and international business from New York University and an MBA from Columbia University.